Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and the best dose of MEK Inhibitor AZD6244
when given together with cetuximab in patients with advanced or refractory solid tumors that
cannot be removed by surgery. MEK inhibitor AZD6244 may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to
grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances
to them. Giving MEK Inhibitor AZD6244 together with cetuximab may kill more tumor cells.